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Abstract
THE DESIGN OF A NEW VAGINAL APPLICATOR FOR DIRECTION MODULATED
BRACHYTHERAPY (DMBT) USING GEANT4 MONTE CARLO SIMULATION CODE
By Moeen Meftahi, MS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science,
at Virginia Commonwealth University.
Virginia Commonwealth University, 2020
Advisor: William Y. Song, Ph.D.
Associate Professor, Department of Radiation Oncology

Purpose: Anisotropy of the

192Ir

source causes a lack of dose coverage at the apex in HDR

vaginal cylinder brachytherapy (VC BT). In this study, we took advantage of the GEANT4
Monte Carlo (MC) simulation code to design a new DMBT vaginal applicator so that it
maintains the dose coverage of the current vaginal cylinder at periphery everywhere while
improving the apex coverage. In addition, since current treatment planning systems (TPS)
considers the whole environment as water according to TG43 formalism, based on the capability
of the MC in the calculation of dose in the material, the effect of inhomogeneity of the vaginal
cylinder in the dose coverage was investigated.

Methods: The new DMBT vaginal applicator was designed to be a 30 mm diameter, single
lumen vaginal cylinder, made of polyphenylsulfone (PPSU) plastic. The central part of the
applicator, which includes the lumen, was considered to be a detachable 8 mm diameter tandem
rod. In order to provide directional modulation, a tungsten rod similar to the dimensions of the
detachable tandem was added to the simulation. The applicator works in two steps. First, we get
a typical dose distribution based on the planning system using the applicator with a detachable
polyetheretherketone (PEEK) plastic tandem in place. Second, the detachable tandem is replaced
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with a tungsten tandem to compensate for the lack of coverage at the apex utilizing a directional
radiation beam generated. The same source dwell positioning is used for both steps, while the
dwell time for the second step is a small fraction of the first step. Furthermore, in order to assess
the effect of VC inhomogeneity, a separate simulation with the same dwell time and position
based on TG43 model was performed and the results were compared. The MATLAB software
was used for data analysis.

Results: The analysis showed that the new applicator can address the lack of coverage at the apex
due to anisotropy (~2 mm), while simultaneously preventing from overdosing the periphery.
Also, the analysis of the data indicated that there is a reduction of dose at the surface of the
cylinder (~7.3%) at the periphery, in comparison to TG43 model.

Conclusion: This new DMBT concept design can be considered as a possible solution for the
lack of apex coverage due to anisotropy as there is a subset of patients who experience
recurrences after brachytherapy, frequently in the vaginal apex. Further, based on the VC
heterogeneity analysis, the reduction of the dose at the surface of the cylinder indicates that
prescribing the dose to VC surface involves additional level of uncertainty.

Key: Vaginal Cylinder, DMBT, Brachytherapy, Inhomogeneity
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Background
Endometrial carcinoma is the most common gynecologic malignancy in the united states. It
constitutes 6% of female cancers, and accounts for 3% of all cancer deaths in women. The
incidence of endometrial cancer has been steadily increasing in the U.S. and worldwide over the
past several decades. The standard treatment for endometrial cancer is a total abdominal
hysterectomy with bilateral salpingo-oophorectomy with or without lymph node dissection.
Adjuvant external beam radiation therapy (EBRT) and/or brachytherapy (BT) are integral
component in the adjuvant therapy of select patients and the radiation is a major component in
the management of inoperable or recurrent endometrial cancers (Alban et al., 2020; Demiral,
2017; Small et al., 2012).
The recent clinical trial (PORTEC-2) compared vaginal BT with EBRT in early-stage
postoperative endometrial cancer patients. The study suggested that vaginal BT is equivalent to
EBRT in preventing local vaginal recurrences and distant metastases (Nout et al., 2010). Vaginal
brachytherapy is also associated with significantly less toxicity when compared to whole pelvic
EBRT (Petereit et al., 1999; Zhang et al., 2016). In addition, High dose-rate (HDR)
brachytherapy is advantageous in that you can achieve a highly conformal dose to the target
under image guidance in an outpatient setting (Zhou et al., 2017). Nonetheless, intracavitary BT
is best reserved for tumors less than 5 mm in thickness (Leung et al., 2019).
Following surgery, the vaginal canal for most patients is roughly cylindrical, and the American
Brachytherapy Society (ABS) recommends a properly sized, single-channel vaginal cylinder
applicator (VC) for BT treatment. The VC is the most common applicator used for high-doserate (HDR) BT and is ideal for patients with a narrow vagina. The region, including the vaginal
cuff, accounts for about 75% of recurrences in endometrial cancer patients. Therefore, vaginal
cuff BT is recommended to decrease the risk of recurrence without adding the toxicities
associated with pelvic radiotherapy (Guy et al., 2019; Kim et al., 2018). Besides the simplicity,
there are a few limiting factors in the application of VCBT that can result in underdosing the
target, in particular, at the apex.
In one study, it is shown that the presence of air gaps around the cylinder can potentially reduce
mucosal dose. They took advantage of post-insertion CT to detect air gaps for 22 patients and
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concluded more than two-third of the patients presented air gaps, in particular at the apex
(Sapienza et al., 2019). Hassouna et al. (Hassouna et al., 2014) has also retrospectively assessed
the presence of air gap in VCBT. Most of the cases they studied had air gap at periphery,
indicating the reduction of dose coverage at target. A shortage of the coverage has been studied
by another group through MRI-based evaluation of vaginal cuff, as well. They figured that suture
material may be restricting access to the vaginal apex and reduce the dose coverage noticeably at
vaginal cuff, resulting in underdosing of at-risk vaginal mucosa (Chapman et al., 2016).
Kim et al.(Kim et al., 2018) studied two different Varian’s VC applicators with the same
diameter, but different top thickness. They showed there is a relatively high loss of coverage at
the apex for the applicator with the thicker top. Another issue involves the significant dose
gradients outside of the cylinders and the variability of the dose falloff relative with the cylinder
size and dose specification point. The effect of the same prescription dose can be significantly
different in two cylinders, for example, 2.3- cm and 3.5-cm diameter, and dramatically different
if prescribed to the cylinder surface vs. 5-mm depth. Thus regardless of treatment regimens, the
way that physicians prescribe the dose can have different clinical outcomes (Ager et al., 2019;
Guy et al., 2019).
Anisotropy of the source is also an important factor that affects the dose coverage at the
apex. The dose distribution produced by the HDR

192Ir

source is inherently anisotropic due

to self-absorption by the high-density source core, oblique filtration by the source capsule and
asymmetric geometry of the source capsule (Sharma et al., 2004), which prevents it from having
a uniform dose coverage at the apex. This phenomenon more commonly affects single-channel
applicators, as these are the most widely used vaginal applicators. Although it can be modified
using multichannel applicators through inverse planning to some extent, this modification can
cause loss of coverage at the other part of the apex (Bahadur et al., 2014; Sabater et al., 2017).
Further, the effect of VC inhomogeneity in treatment planning can affect the dose coverage,
depending on the material, the density, the size, and, the design of the applicator. The current
standard of practice for brachytherapy absorbed dose calculations relies on the AAPM Task
Group 43 TG43 formalism. The dosimetry parameters used in TG- 43 are obtained for a single
BT source located at the center of a fixed-volume, homogeneous, liquid-water phantom. As a
7

result, this method cannot consider the effect of patients’ body shape and the presence of
materials other than water, such as VCs (Abe et al., 2018; Mikell et al., 2012; Rivard et al., 2004,
2009).
In this research, we aim to find a novel solution to remedy the anisotropy of the source for a
single channel VC applicator, so that it does not affect the integrity of dose distribution of a
typical VC while eradicating the anisotropy effect. To do this, we benefit from the concept of
direction modulated brachytherapy (DMBT), which has been used for the design of other
applicators such as cervical, and rectal applicators by other researchers (Bellezzo et al., 2018;
Safigholi et al., 2017). The DMBT applicators utilize a shielded part embedded into them in
order to focus the radiation in a specific direction, while cut the radiation drastically in other
directions simultaneously. Therefore, we design a novel DMBT vaginal cylinder applicator using
the general-purpose GEANT4 Monte Carlo (MC) Simulation code to address the anisotropy of
the source. MC simulation, as gold standard for dosimetry, has been utilized for modeling of the
brachytherapy sources and evaluation of model-based dose calculation algorithms, considering
the effect of inhomogeneity on dose calculation, and dose calculation near the source by other
researchers (Ababneh et al., 2014; Facundo Ballester et al., 2015; Rodrigues et al., 2008). It can
also account for the limitations

related to TG43 with better accuracy for absorbed dose

calculations (Mikell & Mourtada, 2010); therefore, as a second goal, we will assess the effect of
inhomogeneity of VC in the dose coverage and its possible impact on the clinical outcome.

Material and Method
The GEANT4 MC simulation code, toolkit 10.05 was used for the simulation. A typical Varian
Gamma Med Plus source was modeled as described in the literature (Figure 1) (Perez-Calatayud
et al., 2012). The extension of cable was modeled to be 50 mm. Because of the symmetry, 2D
data acquisition was performed, such that the source and the extension of the cable were placed
across the Y axis. The

192Ir

was defined based on all its significant gamma-ray and x-ray

radiations (Ababneh et al., 2014; Chu et al., 1999; X-ray and Gamma-ray Decay Data Standards
for Detector Calibration and Other Applications, 2005).
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Figure 1. a typical structure for Varian HDR source, Gamma Med Plus

Calculation of the Dose Rate Constant
At the first step, Air Kerma Strength (Sk) was calculated. For this purpose, the source was placed
at the center of a 6*6*6 m3 box, filled with air and gridded into voxels with a 5 mm length side.
Up to 2 * 1010 histories were performed (F. Ballester et al., 1997).
At the next step, the source was located at the center of a water phantom 30*30*30 cc, gridded
into voxels with a length side of 0.5 mm. Up to 5 * 109 histories were performed. As pointed out
by Williamson (Williamson JF, 1995), air-kerma estimation was found to be well described by
the linear equation kair /G=Sk +b*y. The slope b describes the increase in kair /G due to buildup of
scatter in the air and the intercept is an estimate of the ratio of the air-kerma rate in free space
and the geometry factor.
Design of the applicator
The new DMBT vaginal applicator was designed to be a 30 mm diameter, single lumen VC,
made of PPSU plastic (currently used in Varian’s VC applicators) , with a density of 1.29 g/cm3
(Sigma-Aldrich, n.d.). The central part of the applicator which includes the lumen was
considered to be a detachable 8 mm diameter tandem rod. In order to provide directional
modulation, a tungsten rod similar to the dimensions of the detachable tandem was added to
simulation. The applicator works in two steps. First, we get a typical dose distribution based on
the planning system using the applicator with a detachable PEEK (currently used in Varian’s VC
applicators) tandem, with a density of 1.3 g/cm3, in place. Second, the detachable tandem is
9

replaced with a tungsten tandem, with a density of 19.3 g/cm3, to compensate for lack of
coverage at the apex utilizing directional radiation beam generated. The same source dwell
positioning is used for both steps, fed from Varian’s TPS, while the dwell time for the second
step is equivalent to three quarter of one fraction of the first step (five fractions). For both steps,
the applicator is placed at a water phantom 30*30*30 cc, gridded into voxels with a side length
of 1 mm. In addition, because the dwell time and positions were fed from a TG43-based TPS
(Table 1), the source was placed at the same condition into a water phantom in order to assess
the effect of the VC inhomogeneity in comparison to TG43 model. The treatment length for this
plan was 5 cm, while prescribing to 5 mm depth. Up to 109 histories were performed for each
dwell position. Furthermore, The MATLAB software was used for data analysis.

DP (mm)

DT (s)

70

132.8

65

110.7

60

105.7

40

19

35

105.9

30

106.2

25

106.2

Table 1, The data obtained from a TG43 TPS. Dwell Positions (DP) across the Y Axis and the Dwell Time (DT) of the source were
used for performing the GEANT4 MC simulations.

Results
The simulated source and the new designed applicator are shown in Figure 2.
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Figure 2, the source and the two-step applicator, designed using GEANT4 MC simulation code. The left, the simulated source.
The middle, the applicator with the PEEK tandem. The right, the applicator with the Tungsten tandem. (the images are not in
scale)

The dose rate constant for Gamma Med Plus calculated from the linear fit was obtained to be
1.122 cGy.h-1.U-1 that is in a good agreement with the consensus data of 1.117 cGy.h-1U-1, with
relative error less than 0.5% (F. Ballester et al., 2001; Perez-Calatayud et al., 2012).

Air Kerma Strength (cGy.cm2.h-1)

Chart Title

y = 2E-06x + 0.0024
R² = 0.4386

0.0035
0.003
0.0025
0.002
0.0015
0.001
0.0005

0
0

50

100

150

200

250

Distance from the Source (mm)

Figure 3, the linear fit for calculation of the air kerma strength
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300

350

A typical dose distribution of the Gamma Med Plus source in the water phantom is given in
Figure 4.

Figure 4, the dose distribution (%) of Gamma Med Plus Source is a water phantom normalized to the dose value at the point
(10,0)

The results from positioning of the source in the VC applicator with PEEK tandem in place, and
those from TG43 is given in the Figure 5. The prescription dose line is shown in red. As
mentioned, the TG43 model does not account for the inhomogeneity of the VC, assuming all the
environment as water as opposed to the MC calculations. Based on the results, the dose
distribution inside the cylinder ( -15 mm < x < 15 mm) is noticeably different from TG43 Model,
so that unlike TG43 Model, the isodose lines 6000 cGy and 4500 cGy cover a larger area inside
the VC applicator.
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Figure 5, isodose lines (cGy) obtained from GEANT4 MC simulations for TG43 model, considering all the environment as water
(Left), and for a 30 mm diameter cylinder, considering the inhomogeneity of the VC applicator (Right). The Prescription dose
line is shown in red.

In addition, the isodose lines slightly shrink at the periphery beyond the VC surface, indicating a
reduction in the dose coverage. In further investigation, a point by point dose analysis at the
boundary of the applicator and water phantom was also performed across the horizontal line y=
50 mm with an interval of 1 mm. The dose values are given in the Table 2. Because the point
x=15 mm is located right at the boundary of the applicator and water phantom, the dose at this
point was extrapolated using the data values x < 15 mm.
13

x

11

12

13

14

15

16

17

18

19

20

4250.81

4041.24

3754.78

3601.63

3364.25

3192.67

3079.86

2815.44

2710.27

2540.59

3959.28

3741.48

3587.04

3276.63

3118.30

3103.05

2925.12

2763.68

2658.72

2466.86

(mm)
TG43

Dose
(cGy)

VC*

Dose
(cGy)

* Vaginal Cylinder
Table 2, Dose per Point at y=50 mm obtained from GEANT4 MC simulations, for TG43 Model (without considering the effect of
VC heterogeneity) as well as a 30 mm diameter VC applicator (with considering the effect of VC heterogeneity)

Comparing the data at the surface of the cylinder (x = 15 mm) indicates that there is a reduction
of 7.3% in dose at the boundary for the VC compared to TG43 (3118.30 vs 3364.25 cGy),
resulting in a cold spot at the surface.
For better analysis, the dose data for the applicator were also categorized into 2 groups and an
exponential function was fitted for each set of data, as given.

4500.00
4000.00

Dose (cGy)

3500.00
3000.00

y = 7967.6e-0.057x
R² = 0.9897

2500.00
2000.00
1500.00
1000.00
500.00

0.00
0

5

10

15

20

x (mm)

Figure 6, Dose per Point at y=50 mm for the TG43 model
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25

4500.00
4000.00
3500.00

y = 7785.7e-0.061x
R² = 0.9746

2500.00
2000.00
1500.00
1000.00

500.00
0.00
0

2

4

6

8

10

12

14

16

x (mm)

Figure 7, Dose per Point at y=50mm & x < 15 mm for a 30 mm diameter Applicator

3500.00
3000.00
2500.00

Dose (cGy)

Dose (cGy)

3000.00

y = 7104.4e-0.052x
R² = 0.9915

2000.00
1500.00
1000.00
500.00
0.00
0

5

10

15

20

x (mm)

Figure 8, Dose per Point at y=50mm & x > 15 mm for a 30 mm diameter Applicator
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As depicted, the attenuation coefficient of the radiation in the water phantom is 0.057 mm-1.
However, when the applicator is in place, the radiation gets attenuated with the coefficients of
0.061 mm-1 inside the applicator, and 0.052 mm-1 outside the applicator in the water phantom.
The multiplication factor for attenuation in the applicator is about 2.3% less than that in the
water phantom, as well.
The coverage at the apex looks pretty similar in both models at the prescription isodose line (red
lines). However, the same type of analysis is given across the horizontal line x=0. The dose
values are shown in the Table 3.

y

74

75

76

77

78

79

80

81

82

83

14581.54

9986.77

7281.08

5632.91

4610.98

3769.89

3154.48

2762.90

2371.04

2123.75

14719.43

9639.88

7270.68

5955.89

4773.11

3973.22

3380.43

2951.93

2569.11

2283.10

(mm)
TG43

Dose
(cGy)

VC*

Dose
(cGy)

* Vaginal Cylinder
Table 3, Dose per Point at x=0 mm obtained from GEANT4 MC simulations, for TG43 Model (without considering the effect of VC
heterogeneity) as well as a 30 mm diameter VC applicator (with considering the effect of VC heterogeneity)

The boundary at the apex is located at y = 76.5 mm. Comparing the dose values at y = 76 mm in
the two models indicates similar results near the apex surface of the applicator (7281.08 vs
7270.68 cGy). However, according to the Table 3 there is an average increase of 5% in dose
values beyond the boundary (y = 76.5 mm) across the line in the water phantom.
Furthermore, the results from the two-step DMBT applicator is shown in Figure 9. The
prescription dose line is shown in red. According to the results, this novel DMBT applicator can
remove the anisotropy dip at the apex and lift up the prescription isodose line up to 2 mm
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without overdosing the other periphery surfaces, i.e., only 3-4 % increase in dose at those
surfaces.

Figure 9, isodose lines (cGy) obtained from GEANT4 MC simulations considering heterogeneities, for a 30 mm diameter
applicator. Left, with the Peek tandem in place. Right, with the Tungsten tandem in place. The Prescription dose line is shown in
red.
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Discussion and Conclusion
It is important to generate a radiation dose distribution that best and uniformly conforms to the
vaginal cuff region as it is the most common place for post-treatment recurrence, through
optimization during treatment planning. The most recent ABS recommendations (released in
2012 (Small et al., 2012)), define optimization as the manipulation of the HDR BT dwell
positions, dwell times, or both. The ABS recommends using an optimization line at the upper
apex or at vaginal cuff as well as the lateral sides of the applicator to avoid unacceptably high
doses to the vaginal apex and any overlying portions of the small bowel. Delivering radiation
dose to the vaginal cuff area that receives uniform prescription dose (Rx) as much as possible is
desired. At minimum, considerable cold spots should be avoided during the planning process as
the risk of recurrence at the vaginal cuff site is approximately 70% [9,10]. Due to the nature of
the source construction, however, the anisotropy of the source will cause underdosage in the
apex area even after the optimization.
A novel single-channel DMBT vaginal applicator is proposed in this research to address the
anisotropy underdosage effect. Based on the results, this applicator can be a possible solution to
compensate for the lack of coverage at the apex due to anisotropy of the source. With the same
dwell positions, the dwell times of the source for this compensation was obtained to be a small
fraction of the total treatment time, i.e., adding few minutes extra to the overall treatment time.
There is a subset of patients who experience recurrence of the disease at the vaginal apex after
vaginal BT. Considering an optimization line as ABS recommends and using the new introduced
DMBT applicator can assure the sufficient coverage of vaginal apex, without overdosing the
lateral periphery. In addition, the new design can be utilized for minimizing of the underdose
effect of the frequent air gaps due to the presence of restricting suture materials at the cuff
through the optimization processes.
The impact of the cylinder applicator heterogeneity was also investigated in this research. It was
shown the inhomogeneity of the cylinder (i.e., density being greater than water) could cause the
creation of cold spot at the surface of the cylinder at the periphery. The main reason for this
phenomenon is the higher density of the VC than water (1.29 g/cm3), which causes gamma and x
rays with lower energies to have more interactions inside the applicator as opposed to when
18

TG43 model is assumed with water everywhere. As a result, the applicator has more absorbed
dose in shallower depth in comparison to when the water is in place. This clarifies why at the
same depth inside the VC including the surface, there is less dose compared to TG43 model. In
addition, radiation gets hardened slightly after passing through the higher density applicator,
which explains the difference among the attenuation coefficients found. The magnitude of cold
spots is strongly dependent on the size of the cylinder for the same plan (with larger the cylinder,
e.g., 35 mm, the bigger the effect), since such determines the level of the beam hardening and
requires further MC simulation studies to characterize.
The magnitude of anisotropy at the apex is slightly different in the two dose calculation models,
as well. This is because of the presence of the lumen at the center of the VC applicator. Since the
channel is not filled with the applicator material (but rather with air), there is no major
interaction and therefore attenuation inside it. Consequently, the dose increases at the apex of the
applicator as opposed to the TG43 model predictions. Moreover, the magnitude of the anisotropy
dip can vary depending on the cylinder top thickness, the material, and the density of the
applicator, which needs further MC simulation studies to characterize.
In conclusion, the novel DMBT cylinder design proposed in this thesis work is a potential
solution to remedy the underdosage at the vaginal apex due to source anisotropy. Such design
may be of clinical benefit. Also, the VC heterogeneity analysis of this research based on MC
simulation calculations indicates that prescribing to the VC surface suffers from extra level of
uncertainty because of the dose reduction at the surface (i.e., cold spots), which should be
considered in treatment planning.
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